SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts
- First Online:
- 310 Downloads
Myocardial ischemia/reperfusion (I/R) injury is partly mediated by thrombin. In support, the functional inhibition of thrombin has been shown to decrease infarct size after I/R. Several cellular responses to thrombin are mediated by a G-protein coupled protease-activated receptor 1 (PAR1).However, the role of PAR1 in myocardial I/R injury has not been well characterized. Therefore, we hypothesized that PAR1 inhibition will reduce the amount of myocardial I/R injury. After we detected the presence of PAR1 mRNA and protein in the rat heart by RT-PCR and immunoblot analysis,we assessed the potential protective role of SCH 79797, a selective PAR1 antagonist, in two rat models of myocardial I/R injury. SCH 79797 treatment immediately before or during ischemia reduced myocardial necrosis following I/R in the intact rat heart. This response was dose-dependent with the optimal dose being 25 μg/kg IV. Likewise, SCH 79797 treatment before ischemia in the isolated heart model reduced infarct size and increased ventricular recovery following I/R in the isolated heart model with an optimal concentration of 1 μM. This reduction was abolished by a PAR1 selective agonist. SCH 79797-induced resistance to myocardial ischemia was abolished by wortmannin, an inhibitor of PI3 kinase; L-NMA, a NOS inhibitor; and glibenclamide, a nonselective KATP channel blocker. PAR1 activating peptide,wortmannin, L-NMA and glibenclamide alone had no effect on functional recovery or infarct size. A single treatment of SCH 79797 administered prior to or during ischemia confers immediate cardioprotection suggesting a potential therapeutic role of PAR1 antagonist in the treatment of injury resulting from myocardial ischemia and reperfusion.
Key wordsmyocardial ischemic reperfusion injury protease-activated receptors thrombin receptor antagonist
Unable to display preview. Download preview PDF.
- 1.Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M (2000) Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl) phenyl]methyl]–7H-pyrrolo [3, 2-f] quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60:1425–1434PubMedCrossRefGoogle Scholar
- 2.Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung W, Damiano BP,D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF (2001) Administration of a potent antagonist of protease-activated receptor- 1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 298:34–42PubMedGoogle Scholar
- 11.Erlich JH, Boyle EM, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N (2000) Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemiareperfusion injury by reducing inflammation. Am J Pathol 157:1849–1862PubMedGoogle Scholar
- 17.Miyuki K,Tetsuya T, Mitsuo T,Akiko M, Satoshi Y, Jun S, Natsuya K, Satoaki M, Jun A,Masao N (2003) The dual effects of nitric oxide synthase inhibitors on ischemia-reperfusion injury in rat hearts. Basic Research in Cardiology V98:319–328Google Scholar
- 18.Much-Ellingsen J, Bugge E, Ytrehus K (1996) Blockade of the KATP-channel by glibenclamide aggravates ischemic injury, and counteracts ischemic preconditioning. Basic Research in Cardiology V91:382–388Google Scholar
- 21.Patel HH, Fryer RM, Gross ER, Bundey RA,Hsu AK, Isbell M,Eusebi LO, Jensen RV, Gullans SR, Insel PA, Nithipatikom K, Gross GJ (2003) 12-lipoxygenase in opioid-induced delayed cardioprotection: gene array, mass spectrometric, and pharmacological analyses. Circ Res 92:676–682PubMedCrossRefGoogle Scholar